EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XNCR, RLAY, Shattuck Labs, Silverback Therapeutics, PRTA, and represent 37.14% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: Shattuck Labs (+$129M), Silverback Therapeutics (+$117M), BIIB (+$62M), SLDB (+$61M), KDNY (+$20M), ORIC (+$15M), GRTS (+$14M), ACIU (+$13M), Kronos Bio (+$12M), NRIX (+$12M).
- Started 31 new stock positions in GOSS, Vincera Pharma, SYRS, BIIB, Bcls Acquisition Corp, Cerevel Therapeutics Hldng I, 5 01 Acquisition Corp Cl A, Bioatla, GRTS, C4 Therapeutics.
- Reduced shares in these 10 stocks: KURA (-$93M), STRO (-$66M), SURF (-$30M), ASMB (-$16M), GLYC (-$14M), NLTX (-$10M), CNST (-$8.1M), Lifesci Acquisition Corp (-$7.8M), DFHTU (-$5.3M), .
- Sold out of its positions in CNST, DFHTU, XCUR, FSDC, FPRX, GLYC, IRWD, Lifesci Acquisition Corp, SVRA, UBX. XOMA, RPRX.
- EcoR1 Capital was a net buyer of stock by $285M.
- EcoR1 Capital has $1.9B in assets under management (AUM), dropping by 32.63%.
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
Companies in the EcoR1 Capital portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Xencor (XNCR) | 10.7 | $198M | 4.5M | 43.63 | ||
| Relay Therapeutics (RLAY) | 7.2 | $133M | 3.2M | 41.56 | ||
| Shattuck Labs | 6.9 | $129M | NEW | 2.5M | 52.41 | |
| Silverback Therapeutics | 6.3 | $117M | NEW | 2.5M | 46.34 | |
| Prothena Corp SHS (PRTA) | 6.1 | $113M | 9.4M | 12.01 | ||
| Oric Pharmaceuticals (ORIC) | 5.6 | $105M | +17% | 3.1M | 33.85 | |
| Mirati Therapeutics (MRTX) | 5.5 | $102M | 464k | 219.64 | ||
| Morphic Hldg (MORF) | 5.1 | $95M | 2.8M | 33.55 | ||
| Anaptysbio Inc Common (ANAB) | 3.7 | $69M | 3.2M | 21.50 | ||
| Biogen Idec Call Option (BIIB) | 3.3 | $62M | NEW | 254k | 244.86 | |
| Solid Biosciences (SLDB) | 3.3 | $61M | NEW | 8.0M | 7.58 | |
| Kura Oncology (KURA) | 3.1 | $58M | -61% | 1.8M | 32.66 | |
| Arcus Biosciences Incorporated (RCUS) | 3.1 | $57M | +21% | 2.2M | 25.96 | |
| Avidity Biosciences Ord (RNA) | 2.9 | $54M | 2.1M | 25.52 | ||
Setup an alertEcoR1 Capital will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Nurix Therapeutics (NRIX) | 2.7 | $51M | +29% | 1.5M | 32.88 | |
| Neoleukin Therapeutics (NLTX) | 2.4 | $44M | -19% | 3.1M | 14.10 | |
| Atreca Cl A Com (BCEL) | 2.1 | $39M | 2.4M | 16.15 | ||
| Akouos (AKUS) | 2.1 | $39M | 2.0M | 19.83 | ||
| Applied Molecular Trans (AMTI) | 1.9 | $35M | 1.2M | 30.77 | ||
| Geron Corporation (GERN) | 1.6 | $30M | 19M | 1.59 | ||
| Gossamer Bio Note (Principal) | 1.5 | $27M | 30M | 0.91 | ||
| Chinook Therapeutics (KDNY) | 1.1 | $20M | NEW | 1.3M | 15.86 | |
| Allovir (ALVR) | 0.9 | $17M | 447k | 38.44 | ||
| Gritstone Oncology Ord (GRTS) | 0.7 | $14M | NEW | 3.4M | 3.94 | |
| Ac Immune Sa SHS (ACIU) | 0.7 | $13M | NEW | 2.4M | 5.17 | |
| Kronos Bio | 0.6 | $12M | NEW | 387k | 29.87 | |
| Syros Pharmaceuticals (SYRS) | 0.6 | $11M | NEW | 1.0M | 10.85 | |
| Vincera Pharma | 0.5 | $10M | NEW | 481k | 20.91 | |
| Aclaris Therapeutics (ACRS) | 0.5 | $9.8M | 1.5M | 6.47 | ||
| Alpine Immune Sciences (ALPN) | 0.5 | $9.3M | 741k | 12.60 | ||
| Bctg Acquisition Corp (BCTG) | 0.5 | $9.2M | 800k | 11.44 | ||
| Iteos Therapeutics (ITOS) | 0.5 | $8.8M | 260k | 33.82 | ||
| Deerfield Healthcare Techn A (DFHT) | 0.4 | $7.5M | NEW | 482k | 15.60 | |
| Cerevel Therapeutics Hldng I | 0.4 | $6.6M | NEW | 400k | 16.58 | |
| C4 Therapeutics | 0.4 | $6.6M | NEW | 200k | 33.13 | |
| Kymera Therapeutics (KYMR) | 0.3 | $6.2M | 100k | 62.00 | ||
| Logicbio Therapeutics (LOGC) | 0.3 | $5.9M | NEW | 775k | 7.63 | |
| Jiya Acquisition Corp | 0.3 | $5.2M | NEW | 500k | 10.30 | |
| Health Sciences Acq Corp 2 Ord SHS (HSAQ) | 0.3 | $5.1M | 400k | 12.81 | ||
| Panacea Acquisition Corp Unit 99/99/9999 (PANA.U) | 0.3 | $5.0M | 390k | 12.76 | ||
| Cyclerion Therapeutics (CYCN) | 0.3 | $4.9M | -41% | 1.6M | 3.06 | |
| Galapagos Nv Spon Adr (GLPG) | 0.2 | $4.6M | NEW | 47k | 98.98 | |
| Dyne Therapeutics (DYN) | 0.2 | $4.5M | 215k | 21.00 | ||
| Ngm Biopharmaceuticals (NGM) | 0.2 | $4.3M | NEW | 144k | 30.29 | |
| Codiak Biosciences | 0.2 | $3.7M | NEW | 115k | 32.30 | |
| Vincera Pharma *w Exp | 0.2 | $3.1M | NEW | 150k | 20.91 | |
| Pmv Pharmaceuticals (PMVP) | 0.2 | $3.1M | 50k | 61.52 | ||
| Gossamer Bio (GOSS) | 0.2 | $2.8M | NEW | 294k | 9.67 | |
| Metacrine Ord (MTCR) | 0.1 | $2.6M | 333k | 7.86 | ||
| Helix Acquisition Corp | 0.1 | $2.3M | NEW | 200k | 11.37 | |
| Bcls Acquisition Corp | 0.1 | $2.2M | NEW | 200k | 11.14 | |
| Lifesci Acquisition Ii Corp | 0.1 | $2.1M | NEW | 200k | 10.67 | |
| Eucrates Biomedical Acqu Cor Unit | 0.1 | $2.1M | NEW | 200k | 10.66 | |
| Consonance Hfw Acquisition C Unit | 0.1 | $2.1M | NEW | 200k | 10.47 | |
| Frazier Lifesciences Acqu Unit | 0.1 | $2.1M | NEW | 200k | 10.38 | |
| 5 01 Acquisition Corp Cl A | 0.1 | $2.0M | NEW | 200k | 10.17 | |
| Sutro Biopharma (STRO) | 0.1 | $2.0M | -96% | 93k | 21.71 | |
| Repare Therapeutics Ord (RPTX) | 0.1 | $1.7M | 50k | 34.30 | ||
| Bioatla | 0.1 | $1.7M | NEW | 50k | 34.02 | |
| Deerfield Healthcare Tech Ac *w Exp (DFHTW) | 0.1 | $1.6M | NEW | 100k | 15.60 | |
| Meiragtx Holdings (MGTX) | 0.1 | $1.4M | 95k | 15.14 | ||
| Turmeric Acquisition Corp Unit | 0.1 | $1.0M | NEW | 100k | 10.27 | |
| Kinnate Biopharma | 0.1 | $995k | NEW | 25k | 39.80 | |
| Intercept Pharmaceuticals In Call Option (ICPT) | 0.0 | $625k | 25k | 24.70 | ||
| Surface Oncology (SURF) | 0.0 | $449k | -98% | 49k | 9.25 | |
| Assembly Biosciences Call Option (ASMB) | 0.0 | $108k | -99% | 18k | 6.07 | |
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2020 Q4 filed Feb. 16, 2021
- EcoR1 Capital 2020 Q3 filed Nov. 16, 2020
- EcoR1 Capital 2020 Q2 filed Aug. 14, 2020
- EcoR1 Capital 2020 Q1 filed May 15, 2020
- EcoR1 Capital 2019 Q4 restated filed Feb. 18, 2020
- EcoR1 Capital 2019 Q4 filed Feb. 14, 2020
- EcoR1 Capital 2019 Q3 filed Nov. 14, 2019
- EcoR1 Capital 2019 Q2 filed Aug. 14, 2019
- EcoR1 Capital 2019 Q1 filed May 15, 2019
- EcoR1 Capital 2018 Q4 filed Feb. 14, 2019
- EcoR1 Capital 2018 Q3 filed Nov. 14, 2018
- EcoR1 Capital 2018 Q2 filed Aug. 14, 2018
- EcoR1 Capital 2018 Q1 filed May 15, 2018
- EcoR1 Capital 2017 Q4 filed Feb. 14, 2018
- EcoR1 Capital 2017 Q3 filed Nov. 14, 2017
- EcoR1 Capital 2017 Q2 filed Aug. 14, 2017